GLP-3 RT 30MG

Unlike current medications like Ozempic (which targets one receptor) or Mounjaro (which targets two), retatrutide acts on three distinct pathways:  

1. GLP-1 (Glucagon-like peptide-1): Reduces appetite by signaling fullness to the brain and slowing stomach emptying.  

2. GIP (Glucose-dependent insulinotropic polypeptide): Improves how the body breaks down sugar and fat, while also potentially reducing the nausea typically associated with GLP-1 drugs.  

3. Glucagon Receptor (GCG): Increases the body’s energy expenditure (metabolic rate) and encourages the liver and fat tissues to burn stored energy. 

Reta is intended for research and laboratory use only.

Not for human consumption.

Not approved by the FDA for diagnosis, treatment, or prevention of any disease.